BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35792468)

  • 1. The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    Atwal A; Snowsill T; Dandy MC; Krum T; Newton C; Evans DG; Crosbie EJ; Ryan NAJ
    Int J Cancer; 2022 Nov; 151(9):1626-1639. PubMed ID: 35792468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE
    Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas.
    Eikenboom EL; van der Werf-'t Lam AS; Rodríguez-Girondo M; Van Asperen CJ; Dinjens WNM; Hofstra RMW; Van Leerdam ME; Morreau H; Spaander MCW; Wagner A; Nielsen M
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e496-e507. PubMed ID: 33887476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature.
    Chinczewski L; Feldhaus FW; Schmitt W; Braicu I; Roser E; Sehouli J
    Anticancer Res; 2023 Apr; 43(4):1655-1662. PubMed ID: 36974818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis.
    Ryan NAJ; Glaire MA; Blake D; Cabrera-Dandy M; Evans DG; Crosbie EJ
    Genet Med; 2019 Oct; 21(10):2167-2180. PubMed ID: 31086306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Caniego-Casas T; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; García Á; Ibarra J; Hakim S; Guarch R; López-Guerrero JA; Poveda A; Palacios J
    Am J Surg Pathol; 2020 May; 44(5):649-656. PubMed ID: 32294063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
    Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
    Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer.
    Post CCB; Stelloo E; Smit VTHBM; Ruano D; Tops CM; Vermij L; Rutten TA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Nout RA; Crosbie EJ; Powell ME; Mileshkin L; Leary A; Bessette P; Putter H; de Boer SM; Horeweg N; Nielsen M; Wezel TV; Bosse T; Creutzberg CL
    J Natl Cancer Inst; 2021 Sep; 113(9):1212-1220. PubMed ID: 33693762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
    Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
    Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
    Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Multi-institution Retrospective Review.
    Jenkins TM; Hanley KZ; Schwartz LE; Cantrell LA; Stoler MH; Mills AM
    Am J Surg Pathol; 2020 Jun; 44(6):782-792. PubMed ID: 31934920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas - institutional experience and review of literature.
    Alphones S; Chatterjee U; Singh A; Das A; Zameer L; Achari R; Bhattacharya A; Roy P
    Childs Nerv Syst; 2021 Aug; 37(8):2521-2530. PubMed ID: 34097097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel.
    Kim SR; Oldfield L; Tone A; Pollett A; Pedersen S; Wellum J; Cesari M; Lajkosz K; Pugh TJ; Ferguson SE
    Int J Gynecol Cancer; 2023 Nov; ():. PubMed ID: 37940339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset.
    Chung J; Negm L; Bianchi V; Stengs L; Das A; Liu ZA; Sudhaman S; Aronson M; Brunga L; Edwards M; Forster V; Komosa M; Davidson S; Lees J; Tomboc P; Samuel D; Farah R; Bendel A; Knipstein J; Schneider KW; Reschke A; Zelcer S; Zorzi A; McWilliams R; Foulkes WD; Bedgood R; Peterson L; Rhode S; Van Damme A; Scheers I; Gardner S; Robbins G; Vanan MI; Meyn MS; Auer R; Leach B; Burke C; Villani A; Malkin D; Bouffet E; Huang A; Taylor MD; Durno C; Shlien A; Hawkins C; Getz G; Maruvka YE; Tabori U;
    J Clin Oncol; 2023 Feb; 41(4):766-777. PubMed ID: 36240479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical features and management of Lynch syndrome-associated ovarian cancer.
    Ran X; Jing H; Li Z
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
    Hodan R; Kingham K; Cotter K; Folkins AK; Kurian AW; Ford JM; Longacre T
    Cancer Med; 2021 Feb; 10(3):1012-1017. PubMed ID: 33369189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype: Implications for Lynch Syndrome Screening.
    Rodriguez M; Kang EY; Farrington K; Cook LS; Le ND; Karnezis AN; Lee CH; Nelson GS; Terzic T; Lee S; Köbel M
    Am J Surg Pathol; 2021 Nov; 45(11):1452-1463. PubMed ID: 34534137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
    Amodio V; Lamba S; Chilà R; Cattaneo CM; Mussolin B; Corti G; Rospo G; Berrino E; Tripodo C; Pisati F; Bartolini A; Aquilano MC; Marsoni S; Mauri G; Marchiò C; Abrignani S; Di Nicolantonio F; Germano G; Bardelli A
    Cancer Cell; 2023 Jan; 41(1):196-209.e5. PubMed ID: 36584674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.